ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today the presentation of posters and oral talks at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place October 22-25, 2023, in Barcelona, Spain.
|
[24-October-2023] |
VALENCIA, Spain, Oct. 24, 2023 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today the presentation of posters and oral talks at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place October 22-25, 2023, in Barcelona, Spain, and Tides Europe 2023, taking place October 30-November 1, 2023, in Amsterdam, NL. Details of the ARTHEx presentations during OTS are below: Date/Time: Monday, October 23, 2023, 16.15–16.30 ARTHEx's posters will be available for viewing during the Poster Sessions I and II, being held on October 24 and October 25, 2023. Titles are listed below:
More information about the OTS meeting can be found here: link. Details of the ARTHEx presentation during Tides Europe is below: Date/Time: Wednesday, November 1, 2023, 08:55 More information about the Tides Europe meeting can be found here: link. About ARTHEx Biotech ARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs. The Company's lead investigational compound, ATX-01, is advancing into clinical development for the treatment of myotonic dystrophy type 1 (DM1), a rare progressive neuromuscular disease. ARTHEx is also advancing its in-house discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically-driven diseases like DM1. The Company headquarters is in Valencia, Spain. For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn. Company Contact Frédéric Legros Investor and Media Contact
SOURCE ARTHEx Biotech |